Synergism of cytotoxicity between cis-diamminedichloro-platinum (II) and cis-diammine(1,1-cyclobutanedicarboxylate) platinum (II)

H. Baba, Y. Maehara, H. Takeuchi, S. Inutsuka, M. Yamamoto, K. Endo, K. Sugimachi

Research output: Contribution to journalArticlepeer-review


In an attempts to increase the antitumor effect and to reduce normal tissue toxicity, the combined cytotoxic effect of cis-Diamminedichloroplatinum (II) (CDDP) and cis-diammine(1,1-cyclobutane dicarboxylate) platinum (II) (CBCDA) was investigated using HeLa and colon 26 cell lines and the combination index (CI). Cytotoxicity of the combination of CDDP and CBDCA on 27 surgically resected specimens of human gastric and colorectal adenocarcinomas was also evaluated using the in vitro succinate dehydrogenase inhibition (SDI) test. The CI values varied with the dose ratio examined (1:1-1:6) of CDDP and CBDCA, with findings that CI<1, synergy, was obtained at fraction affected (Fa)>0.75 for HeLa cells and at Fa<0.9 for colon 26 cells in cases of a dose ratio of 1:1 to 1:2. Of all 27 clinical human adenocarcdinomas, the succinate dehydrogenase (SD) activity was significantly lower in cancer cells concomitantly exposed to both CDDP and CBDCA than in those exposed to either drug alone. These positive effects of a combination of two platinum analogues on human malignant tissues have heretofore not been reported, which would warrant the clinical application of this combination for human malignant tumors.

Original languageEnglish
Pages (from-to)329-333
Number of pages5
JournalInternational journal of oncology
Issue number2
Publication statusPublished - 1994

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Synergism of cytotoxicity between cis-diamminedichloro-platinum (II) and cis-diammine(1,1-cyclobutanedicarboxylate) platinum (II)'. Together they form a unique fingerprint.

Cite this